MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): Preliminary observations

Journal of Magnetic Resonance Imaging

Volumn 7, Issue 1, 1997, Pages 161-163

  Harisinghani, Mukesh G ^a   Saini, Sanjay ^a   Slater, Gregory J ^a   Schnall, Mitchell D ^b   Rifkin, Matthew D ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ALBANY MEDICAL CENTER   (United States)

Author keywords

Contrast; Lymph node; MRI; USPIO

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS CANCER; PELVIS LYMPH NODE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FERRIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARTICLE SIZE; PELVIC NEOPLASMS; PELVIS; SENSITIVITY AND SPECIFICITY;

EID: 0031421869     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.1880070124     Document Type: Article

References (19)

1. De Meester T, Beckerman C, Joseph J, et al. Gallium 67 scanning for carcinoma of the lung. J Thorac Cardiovasc Surg 1976; 72:695-708.
2. Berek J, Hacker N, Fu Y, et al. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastases and survival. Obstet Gynecol 1985; 65:45-52.
3. Weissleder R, Thrall J. The lymphatic system: diagnostic imaging studies. Radiology 1989; 172:315-317.
4. Jung CW, Weissleder R, Josephson L, Bengele H, Brady TJ: Physical properties of MION-46 and AMI-227. In: Proceedings of the 4th annual scientific meeting and exhibition of the International Society for Magnetic Resonance in Medicine. New York: International Society of Magnetic Resonance in Medicine, 1996; 1681.
5. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. JMRI 1994; 301-307.
6. Bengele HH, Palmacci S, Rogers J, Jung CW, Crenshaw J, Josephson L. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 180549, by different routes of administration. Magn Reson Imaging 1994; 12:433-442.
7. Pouliquen D, Jeune LJJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991; 9:275-283.
8. Petersein J, Saini S, Weissleder R. Liver II: iron oxide-based reticuloendothelial contrast agents for MR imaging. MRI Clin North Am 1996; 4:53-60.
9. Vassallo P, Matei C, Heston W, McLachlan S, Koutcher J, Castellino R. AMI-227 enhanced lymphography: usefulness for differentiating reactive from tumor bearing lymph nodes. Radiology 1994; 193:501-506.
10. Guimaraes R, Clement O, Bittoun J, Carnot F, Frija G. MRlymphangiography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR 1994; 201-207.
11. Weissleder R, Elizondo G, Wittenberg J, Lee AS, Josephson L, Brady TJ. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymphnodes with MR imaging. Radiology 1990; 494-498.
12. Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin R, Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. AJNR 1994; 15: 87-94.
13. Anzai Y, Blackwell K, Hirschowitz S, Rogers J, Sato Y, et al. Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. Radiology 1994; 192:709-715.
14. Castellino R, Hoppe R, Blank N, et al. Computed tomography, lymphography, and staging laprotomy: correlations in initial staging of Hodgkin's disease. AJR 1984; 143:37-41.
15. Castellino R. Hodgkin disease: practical concepts for diagnostic radiologist. Radiology 1986; 159:305-310.
16. Dooms G, Hricack H. Radiologic imaging modalities, including magnetic resonance, for evaluating lymph nodes. West J Med 1986; 144:49-57.
17. Buckwalter K, Ellis J, Baker D, et al. Pitfalls in MR imaging of lymphadenopathy after lymphangiography. Radiology 1986; 161: 831-832.
18. Kim S, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastases with MR imaging. Radiology 1994; 190:807-811.
19. Weissleder R, Elizondo G, Josephson L, et al. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989; 171:835-839.